Uses of bremelanotide in therapy for female sexual dysfunction
US10286034B2 · kind B2 · utility
1Cited by
8References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 6, 2017 |
| Grant date | May 14, 2019 |
| Priority date | — |
| Expiry date | Jul 6, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P15/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Use of a subcutaneously administered dose of between about 1.25 mg and 1.75 mg of bremelanotide or a pharmaceutically acceptable salt of bremelanotide for the treatment of female sexual dysfunction in women while reducing or minimizing undesirable side effects.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.